The University of Texas MD Anderson Cancer Center today was awarded over $29 million from the Cancer Prevention and Research Institute of Texas (CPRIT) in support of impactful prevention programs, ...

HOUSTON, NOVEMBER 20, 2025 ― At The University of Texas MD Anderson Cancer Center , research breakthroughs are made possible through seamless ...

The campaign marks the biggest philanthropic effort in the cancer center's history, per a Nov. 12 news release.

Christopher DeVries, a business owner and longtime member of the Texas City-La Marque Chamber of Commerce, died Nov. 13 while ...

NEW YORK, Nov. 18, 2025 /PRNewswire/ -- The DeGregorio Family Foundation with support from the Torrey Coast Foundation has awarded a $500,000 Michael F. Price Memorial Grant to Katy Rezvani, MD, PhD, ...

Using detailed imaging, genetic sequencing and bacterial culturing, researchers unveiled the first evidence of bacteria found ...

The University of Texas MD Anderson Cancer Center today launches its historic $2.5 billion comprehensive philanthropic campaign, Only Possible Here, The Campaign to End Cancer.

Bayer’s Hyrnuo gets US FDA accelerated approval to treat patients with previously treated advanced HER2-mutant NSCLC: Berlin Friday, November 21, 2025, 11:00 Hrs [IST] Following ...

The program, called YesRx, takes in donations and dispenses oral cancer and supportive drugs to those in need, giving away ...

The FDA announced accelerated approval of sevabertinib (Hyrnuo) for HER2-positive non-small cell lung cancer (NSCLC).

Unexpected deposits of bacteria have been found inside brain tumors, apparently affecting how the cancers grow and behave, a ...

Sevabertinib produced “robust and durable” responses in patients with HER2-mutant NSCLC, whether they were previously treated or untreated in the advanced setting, according to Xiuning Le, MD, PhD.